VERVIMO Trademark

Trademark Overview

On Thursday, February 4, 2016, a trademark application was filed for VERVIMO with the United States Patent and Trademark Office. The USPTO has given the VERVIMO trademark a serial number of 86897453. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, February 22, 2018. This trademark is owned by Sun Pharma Global FZE. The VERVIMO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
vervimo

General Information

Serial Number86897453
Word MarkVERVIMO
Filing DateThursday, February 4, 2016
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, February 22, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
Translation of Words in MarkThe wording "VERVIMO" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 9, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSun Pharma Global FZE
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDubai
AE

Trademark Events

Event DateEvent Description
Tuesday, March 6, 2018UNDELIVERABLE MAIL - CORRESP. REMAILED
Thursday, February 22, 2018ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, February 22, 2018ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, July 27, 2017NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, July 27, 2017INQUIRY TO SUSPENSION E-MAILED
Thursday, July 27, 2017SUSPENSION INQUIRY WRITTEN
Wednesday, July 26, 2017LIE CHECKED SUSP - TO ATTY FOR ACTION
Tuesday, January 17, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, January 17, 2017LETTER OF SUSPENSION E-MAILED
Tuesday, January 17, 2017SUSPENSION LETTER WRITTEN
Tuesday, January 17, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 17, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 9, 2017TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, December 2, 2016NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, December 2, 2016INQUIRY TO SUSPENSION E-MAILED
Friday, December 2, 2016SUSPENSION INQUIRY WRITTEN
Tuesday, November 29, 2016LIE CHECKED SUSP - TO ATTY FOR ACTION
Friday, November 18, 2016ASSIGNED TO LIE
Monday, May 16, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, May 16, 2016LETTER OF SUSPENSION E-MAILED
Monday, May 16, 2016SUSPENSION LETTER WRITTEN
Thursday, May 12, 2016ASSIGNED TO EXAMINER
Wednesday, March 23, 2016TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Wednesday, March 23, 2016TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, February 9, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 8, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

vervimo pharmaceutical disorders treatment preparations system diseases mediated inflammatory cancer immunologically